A Phase II Study of MK-3475 in Patents with Advanced Merkel Cell Carcinoma

ID Number 14-2122

Principal Investigator(s)
Philip Friedlander

Department(s) or Division(s)
Hematology and Medical Oncology


The main purpose of this study is to find out how people with advanced Merkel cell cancer respond to a study drug called MK-3475.  MK-3475 is an experimental medication that is being used to stimulate your immune system to destroy cancer cells. We will refer to it from here on as "the study medication".  It works differently than traditional chemotheraqpy agents.  We hope that the study medication will increase the number and function of certain T-cells in your immune system.  T-cells can identify and destroy cancer cells.

Another purpose of this study is for researchers to learn if blood or tumor tests can be used to identify patients who are likely to respond to treatment with the study medication.

Contact Information
Linda Sacris
(212) 824-7309

Recruiting Patients: Yes